
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors



Theseus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies announced the appointment of Steven Stein, M.D. to its Board of Directors.

"We are delighted to welcome Dr. Stein to the Theseus Board as we advance development of our THE-630 and THE-349 programs, while also expanding our early-stage pipeline," said Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus. "Dr. Stein's depth and breadth of oncology expertise, and extensive track record of bringing effective medicines through development and to patients, will be invaluable as we continue to build Theseus as a leading precision oncology company."

Dr. Stein currently serves as Executive Vice President, Chief Medical Officer of the global biopharmaceutical company, Incyte, where he develops strategy for Incyte's therapeutic candidates and oversees verticals including clinical development, regulatory affairs and medical affairs. Previously, he worked at Novartis Pharmaceuticals Corporation, where he most recently served as Senior Vice President, U.S. Clinical Development & Medical Affairs at Novartis Oncology. Dr. Stein previously worked at GSK (formerly GlaxoSmithKline) as Vice President, Global Oncology, Clinical Development and as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein was previously an assistant professor in the Department of Medicine at the University of Pennsylvania, where he had also completed a fellowship in hematology and oncology. Dr. Stein has served as a member of Kura Oncology's Board of Directors since January 2017. He earned his medical degree from the University of Witwatersrand in Johannesburg, South Africa.

Dr. Stein added, "Theseus is backed by a foundation of success in targeted oncology, and I look forward to contributing to their continued growth and development through the Company's near-term clinical milestones, and onward through the complex clinical and regulatory pathways that influence development in the targeted oncology space."

Source: [Theseus Pharmaceuticals](#)

Published on : Wed, 19 Oct 2022